Zydus Cadila receives USFDA okay for Linagliptin Tablets

Written by Ruchika Sharma Published On 2020-10-30T13:00:42+05:30 | Updated On 30 Oct 2020 1:06 PM IST

Zydus Cadila receives USFDA okay for Linagliptin Tablets

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) to market Linagliptin Tablets, 5 mg (US RLD: Tradjenta Tablets).

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 310 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Read also: Zydus Cadila bronchospasm drug Albuterol gets USFDA approval

zydus cadilazydus cadila newsusfdalinagliptin tabletstype 2 diabetes mellitus

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751